STOCK TITAN

Compass Therapeutics to Participate in Upcoming Investor Events

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Compass Therapeutics, Inc. (Nasdaq: CMPX) will participate in investor events at the Stifel Healthcare Conference in New York on November 14, 2023, and the Jefferies London Healthcare Conference on November 16, 2023. The presentations will be available for replay for 90 days on Compass' Events page.
Positive
  • None.
Negative
  • None.

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2023.

Details are as follows:

Stifel Healthcare Conference
Location: New York, NY
Date: Tuesday, November 14, 2023
Time: 9:45am EST
Webcast Link: https://wsw.com/webcast/stifel83/cmpx/2109872

Jefferies London Healthcare Conference
Location: London, U.K.
Date: Thursday, November 16, 2023
Time: 2:30pm GMT (9:30 EST)
Webcast Link: https://wsw.com/webcast/jeff287/cmpx/1872544

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099


FAQ

What events will Compass Therapeutics, Inc. (CMPX) participate in during November 2023?

Compass Therapeutics, Inc. (CMPX) will participate in the Stifel Healthcare Conference in New York on November 14, 2023, and the Jefferies London Healthcare Conference on November 16, 2023.

Where can I find the webcast links for the investor events?

The webcast links for the investor events are available at https://wsw.com/webcast/stifel83/cmpx/2109872 and https://wsw.com/webcast/jeff287/cmpx/1872544.

How long will the presentations be available for replay?

The presentations will be archived for 90 days on Compass' Events page.

Compass Therapeutics, Inc.

NASDAQ:CMPX

CMPX Rankings

CMPX Latest News

CMPX Stock Data

233.90M
102.85M
13.44%
62.82%
1.18%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About CMPX

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond